Market Data
Market Cap₹1,135.1 Cr.
52W High₹508.95
Current Price₹337.2
52W Low₹272.45
Down from 52W High33.7 %
Face Value₹5
Performance
ROCE6.9 %
ROE3.31 %
EPS (TTM)₹4.07
EPS Prev Qtr₹-7.16
EPS Last Year₹3.53
EBITDA Qtr₹21.74 Cr.
Book Value₹158
Financial Health
Debt/Equity0.47
Debt/Profit14.13
Total Assets₹923.22 Cr.
Dividend Yield0.44 %
Promoter Holding58.59 %
Earning Power8.68 %
Valuation
Stock P/E62.44
Industry P/E33.81
Price to Book2.13
Price to Sales1.81
Graham Number₹138.69
Key Metrics
Face Value
₹5
About Bajaj Healthcare Ltd
Healthcare · Pharmaceuticals
Bajaj Healthcare Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹5. Market cap ₹1,135.1 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a healthy promoter holding of 58.59%, indicating strong control and alignment of interests.
- The company has a relatively low debt-to-equity ratio of 0.5, suggesting a conservative capital structure and lower financial risk.
Weaknesses
- The P/E ratio of 61.87 is significantly high, indicating that the stock may be overvalued relative to its earnings.
- The P/B ratio of 2.51 suggests that the market values the company at a premium over its book value.
- The ROCE of 8.04% and ROE of 3.93% are relatively low, indicating inefficient use of capital and lower profitability.
- The dividend yield of 0.45% is very low, offering limited income to investors.
- Net profit of ₹17.63 Cr is low compared to the revenue of ₹627.82 Cr, reflecting thin profit margins.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 147.91 | 161.22 | 153.06 | 165.63 |
| ↳ QoQ Growth | - | +9.0% | -5.1% | +8.2% |
| Expenses | 128.05 | 137.74 | 138.01 | 143.89 |
| Operating Profit | 19.87 | 23.48 | 15.05 | 21.74 |
| OPM % | 13.43% | 14.56% | 9.83% | 13.13% |
| Other Income | 1.65 | 1.65 | 2.96 | 0.81 |
| Interest | 5.56 | 5.88 | 5.57 | 6.09 |
| Depreciation | 7.08 | 7.2 | 7.63 | 7.01 |
| EBITDA | 26.95 | 30.68 | 22.68 | 28.75 |
| EBITDA Margin % | 18.22% | 19.03% | 14.82% | 17.36% |
| Profit Before Tax | 15.96 | 19.24 | -20.81 | 16.46 |
| Tax % | 21.99% | 16.32% | 6.73% | 15.61% |
| Net Profit | 11.11 | 15.67 | -22.85 | 13.7 |
| ↳ QoQ Growth | - | +41.0% | -245.8% | +160.0% |
| EPS | 3.53 | 4.96 | -7.16 | 4.07 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 15.7916 | 16.83 |
| Reserves | 432.8016 | 516.17 |
| Borrowings | 222.62 | 249.09 |
| Other Liabilities | 161.83 | 141.13 |
| Total Liabilities | 833.0462 | 923.22 |
| Fixed Assets | 238.4481 | 247.22 |
| CWIP | 3.4485 | 7.94 |
| Investments | 0 | 0 |
| Other Assets | 591.15 | 668.06 |
| Total Assets | 833.0462 | 923.22 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 21.6205 |
| Cash from Investing Activity | -14.8151 |
| Cash from Financing Activity | -6.3763 |
| Net Cash Flow | 0.4291 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 59.19% | 59.19% | 58.29% | 58.59% |
| FIIs % | 1.12% | 1.18% | 1.98% | 2.19% |
| DIIs % | 2.99% | 2.96% | 2.91% | 1.92% |
| Public % | 26.24% | 26.62% | 28.49% | 29.81% |
| No. of Shareholders | 38,574 | 37,951 | 38,158 | 41,310 |
Major Shareholders (>1%)
- Sajankumar Rameshwarlal BajajPromoter and Promoter Group36.62%
- Anil Champalal JainPromoter and Promoter Group6.05%
- Namrata BajajPromoter and Promoter Group4.85%
- Nihita Bajaj KumarPromoter and Promoter Group4.81%
As of 2026-06-30View all shareholders →